Search - tctmd.com

Displaying 1 - 20 of 67

Sort: Relevancy | Date

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

News Conference News PCR London Valves 2022

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

December 07, 2022

Real-World TEER Outcomes in Primary MR Make Gains, but Questions Remain

News Conference News PCR London Valves 2022

Real-World TEER Outcomes in Primary MR Make Gains, but Questions Remain

December 01, 2022

TAVI Dipped Worldwide in Early COVID-19 Waves, but That’s Not the Whole Story

News Conference News PCR London Valves 2022

TAVI Dipped Worldwide in Early COVID-19 Waves, but That’s Not the Whole Story

November 30, 2022

Big Gains in Function, QoL With Transcatheter TV Replacement: TRISCEND Registry

News Conference News PCR London Valves 2022

Big Gains in Function, QoL With Transcatheter TV Replacement: TRISCEND Registry

November 28, 2022

Earlier Interventions and Later Redos? ‘Mature’ TAVI Still Has Growing Pains

News Conference News PCR London Valves 2022

Earlier Interventions and Later Redos? ‘Mature’ TAVI Still Has Growing Pains

November 28, 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

November 18, 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

News Conference News AHA 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

November 10, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

November 06, 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

High-Sensitivity Troponin Testing on the Rise in the US, but Still Limited

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

November 04, 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

September 23, 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

September 22, 2022

Valve Fracture for ViV TAVI Linked With Higher Mortality

News Conference News TCT 2022

Valve Fracture for ViV TAVI Linked With Higher Mortality

Michael O'Riordan

September 22, 2022

Calcified Nodules Signal Worst Outcome Among OCT-Defined ACS Causes

News Conference News TCT 2022

Calcified Nodules Signal Worst Outcome Among OCT-Defined ACS Causes

September 22, 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

September 21, 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.